US 2015/0104383 A1 · SELENOCYSTEINE MEDIATED HYBRID ANTIBODY MOLECULES

Abstract

The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.

Claims26

Dependent claims

A composition comprising

(a) a hybrid molecule comprising a synthetic molecule and an antibody or antibody fragment selected from the group consisting of Fc, F(ab′)2, Fab, scFv, IgGΔCH2, scFv2CH3, scFv4, scFv3, scFv2, dsFv, and scFv-Fc, wherein the antibody or antibody fragment comprises at least one selenocysteine residue, wherein the at least one selenocysteine residue is located within 300 amino acids of a C-terminus of the antibody or antibody fragment in a constant domain of the antibody or antibody fragment, and wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue, and
(b) a pharmaceutically acceptable carrier.

Dependencies are inferred from the claim text.

Facts

Application

14/579,180Filed 22 Dec 2014

Priority

2 Apr 2007

Published

16 Apr 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 51/10
Peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins: antibodies or immunoglobulins; Fragments thereof , the carrier being…
A61K 47/68
The non-active ingredient being a modifying agent: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/6809
The drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense: antibiotics, e.g. antitumor antibiotics…
A61K 47/6811
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a protein or peptide, e.g. transferrin or…

Family

Application60/909,665Us provisional application · filed 2 Apr 2007

Application12/570,796Continuation · filed 30 Sep 2009

Application14/579,180Continuation

Application12/570,796Continuation in part

US 2010/0104510 A1Published application

US 8,916,159 B2Related patent

US 2015/0104383 A1This patent

From the US filing history. Foreign family members aren’t listed.

Selenocysteine mediated hybrid antibody molecules

Life of this patent

Selenocysteine mediated hybrid antibody molecules

Life of this patent

Abstract

Claims26